Singapore’s Economic Development Board (EDB) announced on 12 March 2020 that it will channel up to USD 10 million to Arcturus Therapeutics, a San Diego-based biotech, to accelerate a single-shot RNA vaccine against the novel coronavirus. The grant, released in tranches tied to development milestones, gives the city-state ownership of any resulting product while allowing global commercialization. Arcturus will collaborate with Duke-NUS Medical School and the National University of Singapore to move the candidate from bench to bedside.
Why Singapore bankrolled a California start-up
The EDB’s decision came only eight weeks after China first disclosed the viral sequence. With local transmission rising across Southeast Asia, Singapore moved fast to diversify its vaccine portfolio beyond large European giants. Officials wanted a nimble platform that could be manufactured quickly inside the country’s own biotech plants if supply chains snapped.
Arcturus offered a self-replicating RNA construct that, in animal models, produces thirty times more viral antigen per microgram than conventional messenger RNA. That potency translates into smaller vials, faster production runs, and lower cost per dose, critical for a nation planning to immunize six million residents and guest workers.
Joseph Payne, chief executive of Arcturus, told investors on 11 March that the company’s “STARR” technology flips the switch on the body’s innate sensors and keeps them on, eliminating the need for a booster. “What we bring to the equation here is a single-shot solution and a 30-fold improvement in dosing. That is why Singapore selected us,” Payne said.
How the money will be spent
The first USD 3 million hit Arcturus accounts on 9 March, bankrolling GMP-grade reagents, animal toxicology, and small-scale fill-finish at Thermo Fisher’s Singapore plant. A second USD 4 million tranche is unlocked once the firm files an investigational new drug application with Singapore’s Health Sciences Authority. The final USD 3 million is payable on first-in-human data that shows neutralizing antibody titers comparable to convalescent plasma.
Duke-NUS will run the Phase I trial at its SingHealth investigational medicine unit, giving the island early readouts on safety and dose range. If results hold, Singapore retains the right to purchase ten million doses at cost for domestic use before any export shipments leave the port.
The American pipeline widens
Arcturus joins two fellow U.S. companies already in the global sprint. Inovio Pharmaceuticals, headquartered in Pennsylvania, designed a DNA plasmid vaccine in three hours after the genomic file was posted online and began Phase I enrollment in Kansas City on 16 March. Moderna, working with the National Institute of Allergy and Infectious Diseases, dosed its first volunteer in Seattle on 16 March with a conventional mRNA candidate, becoming the first developer to reach the clinic.
Dr. Anthony Fauci, director of NIAID, praised the private-sector response on 12 March while warning that “even at rocket speed, a usable vaccine is twelve to eighteen months away.” The Trump administration’s Coronavirus Task Force, led by Vice-President Mike Pence, has pledged to cut every regulatory barrier that does not compromise safety, including parallel running of Phase II and III trials and rolling reviews by the Food and Drug Administration.
Singapore’s deal does not conflict with U.S. interests; Arcturus will still seek FDA clearance and manufacture at its own California facility for the American market. Commerce Secretary Wilbur Ross told Fox Business on 13 March that “any foreign capital that speeds up U.S. innovation is welcome, provided American patients are first in line for doses made on our soil.”
Risks and rivals
Despite the optimism, RNA vaccines have never been licensed for human use, and cold-chain requirements could complicate roll-out in tropical climates. The Arcturus construct must be stored at -80 °C until shortly before injection, a hurdle for island clinics with limited freezer capacity. Company engineers are testing lyophilized formulations that could sit at 4 °C for a week, but stability data will not arrive until late summer.
Competition is also stiff. China’s CanSino and Sinovac have moved their own adenovirus and inactivated vaccines into combined Phase I/II studies, while the University of Queensland and Britain’s Oxford group expect to start trials in April. Singapore officials say they are hedge-betting, signing purchase options with three additional platforms should the Arcturus shot falter.
Dr. Sidney Yee, chief executive of the Diagnostics Development Hub at Singapore’s Agency for Science, Technology and Research, defended the multi-pronged strategy on 13 March. “No one knows which horse crosses the line first; we are backing several so that Singaporeans are not left at the gate,” Yee said.
Global access questions
Under the EDB agreement, Singapore will hold intellectual property generated within its borders, but Arcturus retains commercial rights for North America, Europe, and Japan. Pricing terms have not been disclosed, yet health advocates already worry that smaller economies could be priced out if the pandemic deepens. Médecins Sans Frontières urged the company on 13 March to commit to transparent, at-cost supply for low-income nations.
Paye responded that “access and affordability are baked into our Singapore contract,” noting that the EDB license requires “reasonable pricing” in any market where per-capita GDP falls below USD 12,000. How that clause is enforced will be watched closely by the World Health Organization, which plans to convene vaccine makers in May to draft an allocation framework.
Back in Washington, President Trump signed an USD 8.3 billion emergency package on 6 March that gives HHS authority to buy millions of doses for the Strategic National Stockpile. If Arcturus clears Phase II, the administration could invoke the Defense Production Act to secure priority manufacturing lines, ensuring American health workers and military personnel are protected before exports resume.
The race is on. By Friday the 13th, global infections topped 128,000 and deaths exceeded 4,700, according to Johns Hopkins University. Every week saved in the clinic could translate into thousands of lives spared and billions in economic damage avoided. For a small island nation and a mid-sized California biotech, the stakes could hardly be higher.
